Zoetis (NYSE:ZTS – Get Free Report) had its price objective decreased by equities researchers at Morgan Stanley from $248.00 to $243.00 in a research report issued on Wednesday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Morgan Stanley’s price objective indicates a potential upside of 40.78% from the stock’s current price.
A number of other brokerages also recently issued reports on ZTS. JPMorgan Chase & Co. raised their price target on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Leerink Partners assumed coverage on Zoetis in a research note on Monday, December 2nd. They set an “outperform” rating and a $215.00 target price for the company. Stifel Nicolaus decreased their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, UBS Group assumed coverage on shares of Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $215.00.
Check Out Our Latest Report on Zoetis
Zoetis Stock Performance
Zoetis (NYSE:ZTS – Get Free Report) last posted its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.46 by $0.12. The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. Zoetis’s quarterly revenue was up 11.6% on a year-over-year basis. During the same period in the previous year, the business posted $1.36 earnings per share. As a group, equities research analysts expect that Zoetis will post 5.9 earnings per share for the current fiscal year.
Institutional Trading of Zoetis
A number of large investors have recently made changes to their positions in ZTS. Atlantic Edge Private Wealth Management LLC boosted its stake in shares of Zoetis by 482.8% during the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after buying an additional 140 shares during the period. Darwin Wealth Management LLC purchased a new stake in Zoetis during the 3rd quarter valued at approximately $31,000. First Personal Financial Services acquired a new stake in Zoetis during the 3rd quarter worth approximately $33,000. Capital Performance Advisors LLP purchased a new position in shares of Zoetis in the 3rd quarter valued at approximately $33,000. Finally, Dunhill Financial LLC increased its holdings in shares of Zoetis by 80.6% in the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after purchasing an additional 75 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.
About Zoetis
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Further Reading
- Five stocks we like better than Zoetis
- Energy and Oil Stocks Explained
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- How to Read Stock Charts for Beginners
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.